FDA Warning On Data Integrity: “Sometimes Lawyers Become Too Clever For Their Own Good”
This article was originally published in The Tan Sheet
Executive Summary
How companies handle manufacturing troubles may be more important to the agency than that they happen, top FDA officials indicate, warning that a damaged relationship can affect all of a firm’s interactions with FDA.
You may also be interested in...
FDA’s Call for Quality: Revamped GMP Initiative Stresses Cost Savings
FDA is kicking off phase two of its 21st Century GMP initiative using new authorities and funding under the FDA Safety & Innovation Act. To encourage investment in quality manufacturing systems, the agency is highlighting the cost savings seen by early adopters of quality systems..
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.